免疫組織化学(IHC)の世界市場予測:製品別(抗体、試薬(発色性基質)、キット)、用途別(診断(癌、感染症)、研究、法医学)、エンドユーザー別(病院、診断研究所、学術)

【英語タイトル】Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents (Chromogenic Substrates), Kits), Application (Diagnostics (Cancer, Infectious), Research, Forensic), End User (Hospitals, Diagnostic Laboratories, Academic) - Global Forecast to 2025

MarketsandMarketsが出版した調査資料(BT 4780)・商品コード:BT 4780
・発行会社(調査会社):MarketsandMarkets
・発行日:2020年8月28日
・ページ数:226
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:化学
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥514,800見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥691,600見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥847,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
MarketsandMarkets社は免疫組織化学(IHC)の世界市場が2020年19億から2025年27億ドルまで、年平均6.6%成長すると予測しております。本調査レポートでは、免疫組織化学(IHC)の世界市場について詳細に調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(抗体、試薬、機器、キット)分析、用途別(癌、研究、法医学)分析、エンドユーザー別(病院・診断研究所、学術・研究機関、その他)分析、地域別分析、競争状況、企業評価・情報などを含めております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・免疫組織化学(IHC)の世界市場規模:製品別(抗体、試薬、機器、キット)
・免疫組織化学(IHC)の世界市場規模:用途別(癌、研究、法医学)
・免疫組織化学(IHC)の世界市場規模:エンドユーザー別(病院・診断研究所、学術・研究機関、その他)
・免疫組織化学(IHC)の世界市場規模:地域別
・競争状況
・企業評価・情報
【レポートの概要】

“Increasing incidence of chronic diseases, and technological advancements in IHC are set to drive the IHC market.’’
The global immunohistochemistry market is projected to reach USD 2.7 billion by 2025 from USD 1.9 billion in 2020, at a CAGR of 6.6% during the forecast period. The increasing incidence and prevalence of cancer, technological advancements in IHC, and the availability of reimbursement for IHC tests are the major factors driving the growth of this market. However, the high degree of consolidation is expected to restrain the growth of this market during the forecast period

“By antibodies type, the primary antibodies accounted for the fasted growing antibody segment of the IHC market”
The antibodies segment includes primary antibodies and secondary antibodies. The primary antibodies segment accounted for the fastest growing IHC antibodymarket. Factors such as improved approval rate for therapeutic antibodies by regulatory authorities, increasing adoption of targeted immunotherapy, and increased R&D expenditure of pharmaceutical and biotechnology companies. Also, the mandatory use of primary antibodies in IHC protocols and their extensive application in diverse diagnostic and research areas have resulted in continuous demand for these antibodies.
“By equipment type, the slide-staining systems segment accounted for the largest share of the IHC equipement market”
Based on equipment type, the IHC equipment segment is further divided into slide-staining systems, tissue processing systems, slide scanners, and other equipment (automated cover slippers, microtomes, paraffin dispensers, tissue microarrays, and slide labelers). The slide-staining systems accounted for the largest share of IHC market, by equipment. Development of high-throughput staining systems is one of the major factor driving market growth.

“Asia Pacific: The fastest-growing region in the IHC market.”
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to the large population in emerging economies such as China, India, and Japan; rising prevalence of chronic diseases; rising demand for quality medical care; and the increasing healthcare spending are expected to boost the IHC market in the Asia Pacific.
“North America: the largest share of the IHC market”
North America accounted for the largest share of the IHC market. The large share of this segment can primarily be attributed to the to the presence of major players operating in the IHC market in the US, rising incidence of cancer and infectious diseases, and the increasing adoption of companion diagnostic assay kits.

Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:
• By Respondent– Supply Side- 80%, Demand Side-20%
• By Designation— Executives- 25%, CXOs- 20%, Managers – 55%
• By Region— North America – 50%, Europe – 20%, APAC – 20%, RoW- 10%

The IHC market is dominated by a few globally established players such as F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), PHC Holdings Corporation (Japan), Agilent Technologies, Inc. (US), Merck KGaA (Germany), Sakura Finetek Japan Co., Ltd. (Japan), Abcam plc (UK), Becton, Dickinson and Company (US), Histo-Line Laboratories (Italy), Bio SB, Inc. (US), Diagnostic BioSystems (US), BioGenex (US), Bio-Rad Laboratories, Inc. (US), Biocare Medical, LLC. (US), Miltenyi Biotec (US), CANDOR Bioscience GmbH (Germany), EagleBio (US), Cell Signaling Technology, Inc. (US), Enzo Biochem Inc. (US), BioVision, Inc. (US), Elabscience, Inc. (China), Amos Scientific Pty Ltd. (Australia), Bio-Techne (US), and Jinhua YIDI Medical Appliance CO., LTD. (China)

Research Coverage:
The report segments the IHC market based on region (Asia Pacific, Europe, North America, and RoW), product (antibodies, equipment, kits, and reagents), application (diagnostics, research, and forensic), and end user (hospitals & diagnostic laboratories, academic & research institutes, and other end users).
The report also provides a comprehensive review of market drivers, restraints, challenges, and opportunities in the IHC market

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the IHC market and provides them information on key market drivers, restraints, challenges, and opportunities.

【レポートの目次】

1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 36
1.2.1 INCLUSIONS & EXCLUSIONS 36
1.3 MARKET SCOPE 37
1.3.1 MARKETS COVERED 37
1.3.2 YEARS CONSIDERED FOR THE STUDY 37
1.4 CURRENCY 38
1.5 LIMITATIONS 38
1.6 STAKEHOLDERS 38
1.7 SUMMARY OF CHANGES 39

2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
2.1.1 SECONDARY DATA 40
2.1.2 PRIMARY DATA 41
FIGURE 1 BREAKDOWN OF PRIMARIES: IMMUNOHISTOCHEMISTRY MARKET 41
2.1.3 MARKET DATA ESTIMATION & TRIANGULATION 42
2.1.4 DATA TRIANGULATION 42
FIGURE 2 DATA TRIANGULATION METHODOLOGY 42
2.2 MARKET ESTIMATION METHODOLOGY 43
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE
ANALYSIS-BASED ESTIMATION) 43
FIGURE 4 IMMUNOHISTOCHEMISTRY MARKET SIZE (USD BILLION) 43
FIGURE 5 IMMUNOHISTOCHEMISTRY MARKET: FINAL CAGR
PROJECTIONS (2020−2025) 44
FIGURE 6 IMMUNOHISTOCHEMISTRY MARKET: CAGR PROJECTIONS FROM
THE ANALYSIS OF DEMAND-SIDE DRIVERS AND OPPORTUNITIES 44
2.3 INDUSTRY INSIGHTS 45
2.4 RESEARCH ASSUMPTIONS 45

3 EXECUTIVE SUMMARY 46
FIGURE 7 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2020 VS. 2025 (USD MILLION) 46
FIGURE 8 IMMUNOHISTOCHEMISTRY MARKET SHARE, BY APPLICATION, 2019 46
FIGURE 9 IMMUNOHISTOCHEMISTRY MARKET, BY END USER, 2020−2025 47
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE IMMUNOHISTOCHEMISTRY MARKET 48

4 PREMIUM INSIGHTS 49
4.1 IMMUNOHISTOCHEMISTRY MARKET OVERVIEW 49
FIGURE 11 TECHNOLOGICAL ADVANCEMENTS TO DRIVE MARKET GROWTH 49
4.2 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SHARE,
BY END USER AND COUNTRY (2019) 50
FIGURE 12 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR
THE LARGEST SHARE OF THE ASIA PACIFIC IHC MARKET IN 2019 50
4.3 IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE 50
FIGURE 13 PRIMARY ANTIBODIES SEGMENT WILL CONTINUE TO DOMINATE
THE IHC ANTIBODIES MARKET IN THE FORECAST PERIOD 50

5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
FIGURE 14 IMMUNOHISTOCHEMISTRY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
5.2.1 DRIVERS 52
5.2.1.1 Growing incidence and prevalence of cancer 52
FIGURE 15 CANCER INCIDENCE, BY REGION AND TYPE OF CANCER, 2018 52
5.2.1.2 Technological advancements in IHC 52
5.2.1.3 Availability of reimbursements for IHC tests 53
TABLE 1 CPT CODES FOR IHC PROCEDURES 53
5.2.2 RESTRAINTS 53
5.2.2.1 High degree of consolidation 53
TABLE 2 MAJOR ACQUISITIONS IN THE MARKET, 2015–2020 54
5.2.3 OPPORTUNITIES 54
5.2.3.1 Increasing demand for personalized medicine 54
5.2.4 CHALLENGES 55
5.2.4.1 Dearth of skilled professionals 55
TABLE 3 NUMBER OF PATHOLOGISTS PER 100,000 POPULATION, BY COUNTRY, 2018 55
5.2.4.2 Product failures and recalls 55
5.3 IMPACT OF COVID-19 ON THE IMMUNOHISTOCHEMISTRY MARKET 56

6 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT 58
6.1 INTRODUCTION 59
TABLE 4 IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 59
6.2 ANTIBODIES 59
TABLE 5 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION,
2018–2025 (USD MILLION) 60
TABLE 6 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES,
BY COUNTRY, 2018–2025 (USD MILLION) 60
TABLE 7 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES,
BY COUNTRY, 2018–2025 (USD MILLION) 60
TABLE 8 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION) 61
TABLE 9 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY REGION, 2018–2025 (USD MILLION) 61
TABLE 10 IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2018–2025 (USD MILLION) 61
6.2.1 PRIMARY ANTIBODIES 62
6.2.1.1 Wide applications in diagnostics and research to support the demand for primary antibodies 62
TABLE 11 IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY REGION, 2018–2025 (USD MILLION) 62
TABLE 12 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION) 62
TABLE 13 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES,
BY COUNTRY, 2018–2025 (USD MILLION) 63
TABLE 14 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES,
BY COUNTRY, 2018–2025 (USD MILLION) 63
TABLE 15 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR PRIMARY ANTIBODIES,
BY REGION, 2018–2025 (USD MILLION) 63
6.2.2 SECONDARY ANTIBODIES 64
6.2.2.1 Signal amplification through conjugation and comparatively easy manufacturing to drive the market for secondary antibodies 64
TABLE 16 IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES,
BY REGION, 2018–2025 (USD MILLION) 64
TABLE 17 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION) 64
TABLE 18 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES, BY COUNTRY, 2018–2025 (USD MILLION) 65
TABLE 19 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES,
BY COUNTRY, 2018–2025 (USD MILLION) 65
TABLE 20 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SECONDARY ANTIBODIES,
BY REGION, 2018–2025 (USD MILLION) 65
6.3 REAGENTS 66
TABLE 21 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION,
2018–2025 (USD MILLION) 66
TABLE 22 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS,
BY COUNTRY, 2018–2025 (USD MILLION) 66
TABLE 23 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2018–2025 (USD MILLION) 67
TABLE 24 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY COUNTRY, 2018–2025 (USD MILLION) 67
TABLE 25 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY REGION, 2018–2025 (USD MILLION) 67
TABLE 26 IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2018–2025 (USD MILLION) 68
6.3.1 HISTOLOGICAL STAINS 68
6.3.1.1 Developments in tumor detection and cancer disease progression studies to propel market growth 68
TABLE 27 IMMUNOHISTOCHEMISTRY MARKET FOR HISTOLOGICAL STAINS, BY REGION, 2018–2025 (USD MILLION) 68
6.3.2 BLOCKING SERA AND REAGENTS 69
6.3.2.1 Blocking sera and reagents prevent the nonspecific binding
activity of antibodies 69
TABLE 28 IMMUNOHISTOCHEMISTRY MARKET FOR BLOCKING SERA AND REAGENTS, BY REGION, 2018–2025 (USD MILLION) 69
6.3.3 CHROMOGENIC SUBSTRATES 69
6.3.3.1 Chromogenic substrates segment to register the highest growth during the forecast period 69
TABLE 29 IMMUNOHISTOCHEMISTRY MARKET FOR CHROMOGENIC SUBSTRATES,
BY REGION, 2018–2025 (USD MILLION) 70
6.3.4 FIXATION REAGENTS 70
6.3.4.1 North America is the largest market for fixation reagents 70
TABLE 30 IMMUNOHISTOCHEMISTRY MARKET FOR FIXATION REAGENTS, BY REGION, 2018–2025 (USD MILLION) 70
6.3.5 ORGANIC SOLVENTS 71
6.3.5.1 Organic solvents prevent physical damage in specimens and improve clarity while visualizing tissue samples 71
TABLE 31 IMMUNOHISTOCHEMISTRY MARKET FOR ORGANIC SOLVENTS, BY REGION, 2018–2025 (USD MILLION) 71
6.3.6 DILUENTS 71
6.3.6.1 Diluents are used in the preparation of antibody solutions 71
TABLE 32 IMMUNOHISTOCHEMISTRY MARKET FOR DILUENTS, BY REGION,
2018–2025 (USD MILLION) 71
6.3.7 PROTEOLYTIC ENZYMES 72
6.3.7.1 Proteolytic enzymes improve the accessibility of target antibodies 72
TABLE 33 IMMUNOHISTOCHEMISTRY MARKET FOR PROTEOLYTIC ENZYMES,
BY REGION, 2018–2025 (USD MILLION) 72
6.3.8 OTHER REAGENTS 72
6.3.8.1 Other reagents include antigen retrieval solutions, stabilizers, controls, and mounting solutions. 72
TABLE 34 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER REAGENTS, BY REGION, 2018–2025 (USD MILLION) 73
6.4 EQUIPMENT 73
TABLE 35 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION,
2018–2025 (USD MILLION) 73
TABLE 36 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT,
BY COUNTRY, 2018–2025 (USD MILLION) 73
TABLE 37 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2018–2025 (USD MILLION) 74
TABLE 38 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY COUNTRY, 2018–2025 (USD MILLION) 74
TABLE 39 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY REGION, 2018–2025 (USD MILLION) 74
TABLE 40 IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2018–2025 (USD MILLION) 75
6.4.1 SLIDE-STAINING SYSTEMS 75
6.4.1.1 Development of high-throughput staining systems to
drive market growth 75
TABLE 41 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS,
BY REGION, 2018–2025 (USD MILLION) 75
TABLE 42 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION) 76
TABLE 43 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION) 76
TABLE 44 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION) 76
TABLE 45 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE-STAINING SYSTEMS, BY REGION, 2018–2025 (USD MILLION) 77
6.4.2 TISSUE PROCESSING SYSTEMS 77
6.4.2.1 Technological advancements and need for automation due to shortage of staff to drive market growth 77
TABLE 46 IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS,
BY REGION, 2018–2025 (USD MILLION) 77
TABLE 47 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION) 78
TABLE 48 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION) 78
TABLE 49 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY COUNTRY, 2018–2025 (USD MILLION) 78
TABLE 50 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR TISSUE PROCESSING SYSTEMS, BY REGION, 2018–2025 (USD MILLION) 79
6.4.3 SLIDE SCANNERS 79
6.4.3.1 Development of advanced multiplexed IHC scanners
to drive market growth 79
TABLE 51 IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY REGION, 2018–2025 (USD MILLION) 79
TABLE 52 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS, BY COUNTRY, 2018–2025 (USD MILLION) 80
TABLE 53 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS,
BY COUNTRY, 2018–2025 (USD MILLION) 80
TABLE 54 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS,
BY COUNTRY, 2018–2025 (USD MILLION) 80
TABLE 55 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR SLIDE SCANNERS,
BY REGION, 2018–2025 (USD MILLION) 81
6.4.4 OTHER EQUIPMENT 81
TABLE 56 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY REGION, 2018–2025 (USD MILLION) 81
TABLE 57 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT, BY COUNTRY, 2018–2025 (USD MILLION) 81
TABLE 58 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT,
BY COUNTRY, 2018–2025 (USD MILLION) 82
TABLE 59 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT,
BY COUNTRY, 2018–2025 (USD MILLION) 82
TABLE 60 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER EQUIPMENT,
BY REGION, 2018–2025 (USD MILLION) 82
6.5 KITS 83
TABLE 61 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION,
2018–2025 (USD MILLION) 83
TABLE 62 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR KITS,
BY COUNTRY, 2018–2025 (USD MILLION) 83
TABLE 63 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY,
2018–2025 (USD MILLION) 84
TABLE 64 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY COUNTRY,
2018–2025 (USD MILLION) 84
TABLE 65 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY REGION,
2018–2025 (USD MILLION) 84
TABLE 66 IMMUNOHISTOCHEMISTRY MARKET FOR KITS, BY TYPE,
2018–2025 (USD MILLION) 85
6.5.1 HUMAN IMMUNOHISTOCHEMISTRY KITS 85
6.5.1.1 Increasing focus on cancer research to fuel market growth 85
6.5.2 ANIMAL IMMUNOHISTOCHEMISTRY KITS 85
6.5.2.1 Increasing preclinical drug testing to drive market growth 85

7 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 67 IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 87
7.2 DIAGNOSTIC APPLICATIONS 87
TABLE 68 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,
BY REGION, 2018–2025 (USD MILLION) 87
TABLE 69 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 88
TABLE 70 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 88
TABLE 71 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 88
TABLE 72 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2018–2025 (USD MILLION) 89
TABLE 73 IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,
BY DISEASE, 2020–2025 (USD MILLION) 89
7.2.1 CANCER 89
7.2.1.1 Growing use of IHC tests for cancer diagnostics to fuel the
market growth 89
TABLE 74 IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION,
2018–2025 (USD MILLION) 91
TABLE 75 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER,
BY COUNTRY, 2018–2025 (USD MILLION) 91
TABLE 76 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2018–2025 (USD MILLION) 91
TABLE 77 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY COUNTRY, 2018–2025 (USD MILLION) 92
TABLE 78 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR CANCER, BY REGION,
2018–2025 (USD MILLION) 92
7.2.2 INFECTIOUS DISEASES 92
7.2.2.1 Growing prevalence of infectious diseases and rising awareness
of early diagnosis to propel market growth 92
TABLE 79 IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018–2025 (USD MILLION) 93
TABLE 80 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 93
TABLE 81 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 93
TABLE 82 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES,
BY COUNTRY, 2018–2025 (USD MILLION) 94
TABLE 83 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR INFECTIOUS DISEASES,
BY REGION, 2018–2025 (USD MILLION) 94
7.2.3 NEPHROLOGICAL DISEASES 94
7.2.3.1 Wide application of IHC in transplant rejection is expected to
support market growth 94
TABLE 84 IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES,
BY REGION, 2018–2025 (USD MILLION) 95
TABLE 85 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 95
TABLE 86 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 95
TABLE 87 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 96
TABLE 88 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2018–2025 (USD MILLION) 96
7.2.4 AUTOIMMUNE DISEASES 96
7.2.4.1 Availability of numerous primary antibodies and rapid processing
of results make IHC a favorable diagnostic approach 96
TABLE 89 IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES,
BY REGION, 2018–2025 (USD MILLION) 97
TABLE 90 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 97
TABLE 91 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 97
TABLE 92 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES,
BY COUNTRY, 2018–2025 (USD MILLION) 98
TABLE 93 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR AUTOIMMUNE DISEASES,
BY REGION, 2018–2025 (USD MILLION) 98
7.2.5 NEUROLOGICAL DISEASES 98
7.2.5.1 Increasing global burden of neurological diseases to
propel market growth 98
TABLE 94 IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES,
BY REGION, 2018–2025 (USD MILLION) 99
TABLE 95 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 99
TABLE 96 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 99
TABLE 97 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 100
TABLE 98 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2018–2025 (USD MILLION) 100
7.2.6 OTHER DISEASES 100
TABLE 99 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY REGION, 2018–2025 (USD MILLION) 100
TABLE 100 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES, BY COUNTRY, 2018–2025 (USD MILLION) 101
TABLE 101 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES,
BY COUNTRY, 2018–2025 (USD MILLION) 101
TABLE 102 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES,
BY COUNTRY, 2018–2025 (USD MILLION) 101
TABLE 103 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER DISEASES,
BY REGION, 2018–2025 (USD MILLION) 102
7.3 RESEARCH APPLICATIONS 102
TABLE 104 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS,
BY REGION, 2018–2025 (USD MILLION) 102
TABLE 105 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 102
TABLE 106 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 103
TABLE 107 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 103
TABLE 108 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2018–2025 (USD MILLION) 103
7.3.1 DRUG DEVELOPMENT & TESTING 104
7.3.1.1 Quantitative image analysis makes IHC techniques ideal
for drug testing 104
7.3.2 OTHER RESEARCH APPLICATIONS 104
TABLE 109 IMMUNOHISTOCHEMISTRY MARKET FOR RESEARCH APPLICATIONS,
BY TYPE, 2018–2025 (USD MILLION) 104
7.4 FORENSIC APPLICATIONS 105
TABLE 110 IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS,
BY REGION, 2018–2025 (USD MILLION) 105
TABLE 111 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 105
TABLE 112 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 106
TABLE 113 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 106
TABLE 114 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR FORENSIC APPLICATIONS,
BY REGION, 2018–2025 (USD MILLION) 106

8 IMMUNOHISTOCHEMISTRY MARKET, BY END USER 107
8.1 INTRODUCTION 108
TABLE 115 IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 108
8.2 HOSPITALS & DIAGNOSTIC LABORATORIES 108
8.2.1 INCREASING INCIDENCE OF CANCER AND INFECTIOUS DISEASES TO INCREASE TESTING VOLUME IN CLINICAL LABORATORIES 108
TABLE 116 IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018–2025 (USD MILLION) 109
TABLE 117 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS
& DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION) 109
TABLE 118 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION) 109
TABLE 119 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION) 110
TABLE 120 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018–2025 (USD MILLION) 110
8.3 ACADEMIC & RESEARCH INSTITUTES 110
8.3.1 INCREASING USE OF IHC TESTS FOR DRUG DEVELOPMENT AND DISEASE DIAGNOSIS TO SUPPORT MARKET GROWTH 110
TABLE 121 IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018–2025 (USD MILLION) 111
TABLE 122 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC
& RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION) 111
TABLE 123 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION) 111
TABLE 124 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION) 112
TABLE 125 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018–2025 (USD MILLION) 112
8.4 OTHER END USERS 112
TABLE 126 IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION) 113
TABLE 127 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER
END USERS, BY COUNTRY, 2018–2025 (USD MILLION) 113
TABLE 128 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2018–2025 (USD MILLION) 113
TABLE 129 APAC: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY COUNTRY, 2018–2025 (USD MILLION) 114
TABLE 130 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR OTHER END USERS,
BY REGION, 2018–2025 (USD MILLION) 114

9 IMMUNOHISTOCHEMISTRY MARKET, BY REGION 115
9.1 INTRODUCTION 116
TABLE 131 IMMUNOHISTOCHEMISTRY MARKET, BY REGION,
2018–2025 (USD MILLION) 116

9.2 NORTH AMERICA 117
FIGURE 16 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT 117
TABLE 132 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 118
TABLE 133 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 118
TABLE 134 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES,
BY TYPE, 2018–2025 (USD MILLION) 118
TABLE 135 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS,
BY TYPE, 2018–2025 (USD MILLION) 119
TABLE 136 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT,
BY TYPE, 2018–2025 (USD MILLION) 119
TABLE 137 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 119
TABLE 138 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 120
TABLE 139 NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 120
9.2.1 US 120
9.2.1.1 US is the largest country-level market for immunohistochemistry 120
TABLE 140 US: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 121
TABLE 141 US: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2018–2025 (USD MILLION) 121
TABLE 142 US: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2018–2025 (USD MILLION) 122
TABLE 143 US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 122
TABLE 144 US: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,
BY DISEASE, 2018–2025 (USD MILLION) 122
TABLE 145 US: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 123
9.2.2 CANADA 123
9.2.2.1 Increasing cancer cases in Canada to support market growth 123
TABLE 146 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 123
TABLE 147 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 124
TABLE 148 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION) 124
TABLE 149 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 124
TABLE 150 CANADA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 125
TABLE 151 CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 125

9.3 EUROPE 125
TABLE 152 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 126
TABLE 153 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 126
TABLE 154 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 126
TABLE 155 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE, 2018–2025 (USD MILLION) 127
TABLE 156 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION) 127
TABLE 157 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 127
TABLE 158 EUROPE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 128
TABLE 159 EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 128
9.3.1 GERMANY 128
9.3.1.1 Germany to dominate the European IHC market 128
TABLE 160 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 129
TABLE 161 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 129
TABLE 162 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION) 129
TABLE 163 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 130
TABLE 164 GERMANY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 130
TABLE 165 GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 130
9.3.2 FRANCE 131
9.3.2.1 Increasing use of IHC in cancer diagnosis and research to drive market growth 131
TABLE 166 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 131
TABLE 167 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 131
TABLE 168 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION) 132
TABLE 169 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 132
TABLE 170 FRANCE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 132
TABLE 171 FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 133
9.3.3 UK 133
9.3.3.1 Increasing number of cancer research studies to support
market growth 133
TABLE 172 UK: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 133
TABLE 173 UK: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2018–2025 (USD MILLION) 134
TABLE 174 UK: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2018–2025 (USD MILLION) 134
TABLE 175 UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 134
TABLE 176 UK: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS,
BY DISEASE, 2018–2025 (USD MILLION) 135
TABLE 177 UK: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 135
9.3.4 ITALY 135
9.3.4.1 High incidence of cancer to support market growth in Italy 135
TABLE 178 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 136
TABLE 179 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2018–2025 (USD MILLION) 136
TABLE 180 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2018–2025 (USD MILLION) 136
TABLE 181 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 137
TABLE 182 ITALY: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 137
TABLE 183 ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 137
9.3.5 SPAIN 138
9.3.5.1 Increasing demand for personalized medicine will drive the demand for IHC tests to find potential biomarkers 138
TABLE 184 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 138
TABLE 185 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 138
TABLE 186 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION) 139
TABLE 187 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 139
TABLE 188 SPAIN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 139
TABLE 189 SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 140
9.3.6 REST OF EUROPE 140
TABLE 190 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 140
TABLE 191 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2018–2025 (USD MILLION) 140
TABLE 192 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2018–2025 (USD MILLION) 141
TABLE 193 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 141
TABLE 194 ROE: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 141
TABLE 195 ROE: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 142
9.4 ASIA PACIFIC 142
TABLE 196 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 142
FIGURE 17 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT 143
TABLE 197 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 143
TABLE 198 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES,
BY TYPE, 2018–2025 (USD MILLION) 144
TABLE 199 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS,
BY TYPE, 2018–2025 (USD MILLION) 144
TABLE 200 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT,
BY TYPE, 2018–2025 (USD MILLION) 144
TABLE 201 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 145
TABLE 202 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 145
TABLE 203 ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 145
9.4.1 JAPAN 146
9.4.1.1 Japan to dominate the Asia Pacific immunohistochemistry market 146
TABLE 204 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 146
TABLE 205 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 146
TABLE 206 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION) 147
TABLE 207 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 147
TABLE 208 JAPAN: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 147
TABLE 209 JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 148
9.4.2 CHINA 148
9.4.2.1 China to register the highest growth during the forecast period 148
TABLE 210 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 148
TABLE 211 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 149
TABLE 212 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION) 149
TABLE 213 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 149
TABLE 214 CHINA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 150
TABLE 215 CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 150
9.4.3 INDIA 150
9.4.3.1 India is a key destination for high-end pathology and diagnostic services 150
TABLE 216 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 151
TABLE 217 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 151
TABLE 218 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION) 151
TABLE 219 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 152
TABLE 220 INDIA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 152
TABLE 221 INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 152
9.4.4 REST OF ASIA PACIFIC 153
TABLE 222 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 153
TABLE 223 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 153
TABLE 224 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION) 154
TABLE 225 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 154
TABLE 226 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 154
TABLE 227 ROAPAC: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 155
9.5 REST OF THE WORLD 155
TABLE 228 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY REGION,
2018–2025 (USD MILLION) 155
TABLE 229 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 155
TABLE 230 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2018–2025 (USD MILLION) 156
TABLE 231 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR REAGENTS, BY TYPE,
2018–2025 (USD MILLION) 156
TABLE 232 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2018–2025 (USD MILLION) 156
TABLE 233 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 157
TABLE 234 ROW: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 157
TABLE 235 ROW: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 157
9.5.1 LATIN AMERICA 158
9.5.1.1 Increasing incidence of cancer in Latin America is driving
market growth 158
TABLE 236 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 158
TABLE 237 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE, 2018–2025 (USD MILLION) 158
TABLE 238 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE, 2018–2025 (USD MILLION) 158
TABLE 239 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 159
TABLE 240 LATAM: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 159
TABLE 241 LATAM: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 159
9.5.2 MIDDLE EAST AND AFRICA 160
9.5.2.1 Government initiatives focused on boosting healthcare infrastructure development to drive market growth 160
TABLE 242 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 160
TABLE 243 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR ANTIBODIES, BY TYPE,
2018–2025 (USD MILLION) 160
TABLE 244 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR EQUIPMENT, BY TYPE,
2018–2025 (USD MILLION) 161
TABLE 245 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 161
TABLE 246 MEA: IMMUNOHISTOCHEMISTRY MARKET FOR DIAGNOSTIC APPLICATIONS, BY DISEASE, 2018–2025 (USD MILLION) 161
TABLE 247 MEA: IMMUNOHISTOCHEMISTRY MARKET, BY END USER,
2018–2025 (USD MILLION) 162

10 COMPETITIVE LANDSCAPE 163
10.1 INTRODUCTION 163
10.2 MARKET RANKING ANALYSIS 163
FIGURE 18 COMPANY RANKING IN THE IMMUNOHISTOCHEMISTRY MARKET, 2019 163
10.3 MARKET EVALUATION FRAMEWORK 164
TABLE 248 MARKET EVALUATION FRAMEWORK: PRODUCT DEVELOPMENT & LAUNCH—THE MAJOR STRATEGY ADOPTED BY PLAYERS 164
10.4 COMPETITIVE SCENARIO 164
10.4.1 KEY PRODUCT LAUNCHES 164
10.4.2 KEY COLLABORATIONS, PARTNERSHIPS, AND AGREEMENTS 165
10.4.3 KEY EXPANSIONS 166
10.4.4 KEY ACQUISITIONS 166

11 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 167
11.1 OVERVIEW 167
11.2 GLOBAL IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX 167
11.2.1 STARS 167
11.2.2 EMERGING LEADERS 167
11.2.3 PERVASIVE 167
11.2.4 EMERGING COMPANIES 168
FIGURE 19 GLOBAL IMMUNOHISTOCHEMISTRY MARKET: COMPANY
EVALUATION MATRIX, 2019 168
11.3 COMPANY PROFILES 169
(Business Overview, Products Offered, Recent Developments, MnM View)*
11.3.1 F. HOFFMANN-LA ROCHE AG 169
FIGURE 20 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2019) 169
11.3.2 DANAHER CORPORATION 174
FIGURE 21 DANAHER CORPORATION: COMPANY SNAPSHOT (2019) 174
11.3.3 AGILENT TECHNOLOGIES, INC. 178
FIGURE 22 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2019) 178
11.3.4 MERCK KGAA 182
FIGURE 23 MERCK KGAA: COMPANY SNAPSHOT (2019) 182
11.3.5 BIO-RAD LABORATORIES, INC. 187
FIGURE 24 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019) 187
11.3.6 PHC HOLDINGS CORPORATION 189
11.3.7 BIO-TECHNE CORPORATION 192
FIGURE 25 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2019) 192
11.3.8 ABCAM PLC 194
FIGURE 26 ABCAM COMPANY: COMPANY SNAPSHOT (2019) 194
11.3.9 BECTON, DICKINSON AND COMPANY 197
FIGURE 27 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2019) 197
11.3.10 PERKINELMER 201
FIGURE 28 PERKINELMER: COMPANY SNAPSHOT (2019) 201
11.3.11 CELL SIGNALING TECHNOLOGY, INC. 204
11.3.12 BIO SB, INC. 208
11.3.13 MILTENYI BIOTEC 212
11.3.14 CANDOR BIOSCIENCE GMBH 215
11.3.15 SAKURA FINETEK JAPAN CO., LTD. 216
11.3.16 EAGLEBIO 219
11.3.17 BIOCARE MEDICAL, LLC 220
11.3.18 ELABSCIENCE, INC. 223
11.3.19 BIOGENEX 224
11.3.20 DIAGNOSTIC BIOSYSTEMS 226
*Details on Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.

12 APPENDIX 230
12.1 DISCUSSION GUIDE 230
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 233
12.3 AVAILABLE CUSTOMIZATIONS 235
12.4 RELATED REPORTS 235
12.5 AUTHOR DETAILS 236


★調査レポート[免疫組織化学(IHC)の世界市場予測:製品別(抗体、試薬(発色性基質)、キット)、用途別(診断(癌、感染症)、研究、法医学)、エンドユーザー別(病院、診断研究所、学術)] (コード:BT 4780)販売に関する免責事項を必ずご確認ください。
★調査レポート[免疫組織化学(IHC)の世界市場予測:製品別(抗体、試薬(発色性基質)、キット)、用途別(診断(癌、感染症)、研究、法医学)、エンドユーザー別(病院、診断研究所、学術)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆